Predicting Anti-inflammatory Peptides by Ensemble Machine Learning and Deep Learning.

Journal: Journal of chemical information and modeling
Published Date:

Abstract

Inflammation is a biological response to harmful stimuli, aiding in the maintenance of tissue homeostasis. However, excessive or persistent inflammation can precipitate a myriad of pathological conditions. Although current treatments such as NSAIDs, corticosteroids, and immunosuppressants are effective, they can have side effects and resistance issues. In this backdrop, anti-inflammatory peptides (AIPs) have emerged as a promising therapeutic approach against inflammation. Leveraging machine learning methods, we have the opportunity to accelerate the discovery and investigation of these AIPs more effectively. In this study, we proposed an advanced framework by ensemble machine learning and deep learning for AIP prediction. Initially, we constructed three individual models with extremely randomized trees (ET), gated recurrent unit (GRU), and convolutional neural networks (CNNs) with attention mechanism and then used stacking architecture to build the final predictor. By utilizing various sequence encodings and combining the strengths of different algorithms, our predictor demonstrated exemplary performance. On our independent test set, our model achieved an accuracy, MCC, and F1-score of 0.757, 0.500, and 0.707, respectively, clearly outperforming other contemporary AIP prediction methods. Additionally, our model offers profound insights into the feature interpretation of AIPs, establishing a valuable knowledge foundation for the design and development of future anti-inflammatory strategies.

Authors

  • Jiahui Guan
    Nvidia, Boston, United States.
  • Lantian Yao
    Warshel Institute for Computational Biology, The Chinese University of Hong Kong, Shenzhen, PR China, and also in the School of Science and Engineering, The Chinese University of Hong Kong, Shenzhen, PR China.
  • Chia-Ru Chung
    Department of Computer Science and Information Engineering, National Central University.
  • Peilin Xie
    Kobilka Institute of Innovative Drug Discovery, School of Medicine, The Chinese University of Hong Kong, Shenzhen 518172, China.
  • Yilun Zhang
    School of Medicine, The Chinese University of Hong Kong, Shenzhen 518172, China.
  • Junyang Deng
    School of Medicine, The Chinese University of Hong Kong, Shenzhen 518172, China.
  • Ying-Chih Chiang
    Kobilka Institute of Innovative Drug Discovery, School of Medicine, The Chinese University of Hong Kong, Shenzhen, China.
  • Tzong-Yi Lee